Stock data
Nuvectis Pharma, Inc. (NVCT)
Nuvectis Pharma, Inc. (NVCT) reported net income of -US$26.44M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$27.57M | -US$26.44M | — |
| 2024 | — | — | -US$19.85M | -US$19.00M | — |
| 2023 | — | — | -US$22.90M | -US$22.26M | — |
| 2022 | — | — | -US$19.23M | -US$19.09M | — |
| 2021 | — | — | -US$12.89M | -US$12.89M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$7.02M | — |
| 2026-03-31 | — | -US$6.05M | — |
| 2025-12-31 | — | -US$7.31M | — |
| 2025-09-30 | — | -US$7.46M | — |
| 2025-06-30 | — | -US$6.33M | — |
| 2025-03-31 | — | -US$5.33M | — |
| 2024-12-31 | — | -US$6.25M | — |
| 2024-09-30 | — | -US$4.15M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.